Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 5Recruiting 3Terminated 2Completed 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 14Prostatic Neoplasms 11Neoplasm Metastasis 7Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Salivary Gland Neoplasms 3Histiocytoma, Malignant Fibrous 3Head and Neck Neoplasms 3Dermatofibrosarcoma 3Bone Neoplasms 3Urinary Bladder Neoplasms 2Solid Tumors 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Rhabdomyosarcoma 2Neoplasms 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Esthesioneuroblastoma, Olfactory 2Carcinoma, Transitional Cell 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Recurrent Squamous Cell Lung Carcinoma 1Pathologic Complete Response 1Ovarian Neoplasms 1

Interventions

pertuzumab 1Trastuzumab 1Fluorodeoxyglucose F18 1Docetaxel 1Carboplatin 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × HER2-positive Breast Cancer × Docetaxel × Clear all
NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

University of Rochester

Phase 2 Withdrawn
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡